Sahajanand Medical Technologies Limited has received a Summons dated October 16, 2026 (received on October 23, 2026) issued by the Superintendent/Appraiser/Senior Intelligence Officer of DGGI, Mumbai Zonal Unit. The summons was issued under Section 70 of the Central Goods and Services Tax Act, 2017 to the company's GSTIN 27AAFCS7694L1ZI.
The summons has been issued for initiation of inquiry under the CGST Act, specifically for verification of books of accounts. The document states that the summons relates to giving evidence in relation to GST compliance for re-imbursements made to foreign subsidiaries for clinical trials.
The company has stated that the summons does not specify any particular violations or contraventions at this stage. The disclosure explicitly mentions that there is no material financial, operational, or business impact quantifiable in monetary terms at this stage of the proceedings.
The company is fully cooperating with the authorities and will provide all necessary information as required. The company has committed to keeping the stock exchanges informed of any further significant developments in this matter.
The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended.
The authority details are: Superintendent/Appraiser/Senior Intelligence Officer of DGGI Branch, Zonal Unit Mumbai, NTC House, 1st floor, Ballard Estate, Fort, Mumbai - 400001.
Financial Impact
No material financial impact disclosed at this stage. Financial impact not quantified in the disclosure.